セフォゾプラン
- 関
- cefozopran hydrochloride
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/07/22 13:54:30」(JST)
[Wiki en表示]
Cefozopran
|
Systematic (IUPAC) name |
(6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)- 2-methoxyiminoacetyl]amino]-3-(imidazo[2,3-f]pyridazin- 4-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylate
|
Clinical data |
AHFS/Drugs.com |
International Drug Names |
Identifiers |
CAS Registry Number |
113359-04-9 Y |
ATC code |
J01DE03 |
PubChem |
CID: 9571080 |
ChemSpider |
7845546 N |
UNII |
1LG87K28LW Y |
KEGG |
D01052 Y |
ChEMBL |
CHEMBL1276663 N |
Chemical data |
Formula |
C19H17N9O5S2 |
Molecular mass |
515.52 g/mol |
SMILES
-
O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)/c3nc(sn3)N)Cn5c4cccn[n+]4cc5)C([O-])=O
|
InChI
-
InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11-/t12-,17-/m1/s1 N
-
Key:QDUIJCOKQCCXQY-WHJQOFBOSA-N N
|
N (what is this?) (verify) |
Cefozopran (INN) is a fourth-generation cephalosporin.
Spectrum of bacterial susceptibility and resistance
Most of the strains of Stenotrophomonas maltophilia have developed resistance toward cefozopran.[1]
References
- ^ "Cefozopran Susceptibility and Resistance Data" (PDF). Retrieved 23 July 2013.
Antibacterials: cell envelope antibiotics (J01C-J01D)
|
|
Intracellular |
- inhibit peptidoglycan subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
|
|
Glycopeptide |
- inhibit PG chain elongation: Vancomycin# (Oritavancin
- Telavancin)
- Teicoplanin (Dalbavancin)
- Ramoplanin
|
|
β-lactams/
(inhibit PBP
cross-links) |
|
|
Other |
- polymyxins/detergent
- depolarizing
- hydrolyze NAM-NAG
- Gramicidin
- Isoniazid
- Teixobactin
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Index of bacterial disease
|
|
Description |
|
|
Disease |
- Gram-positive firmicutes
- Gram-positive actinobacteria
- Gram-negative proteobacteria
- Gram-negative non-proteobacteria
- Cholera
- Tuberculosis
|
|
Treatment |
- Antibiotics
- cell wall
- nucleic acid
- mycobacteria
- protein synthesis
- other
- Antibodies
|
|
|
English Journal
- Fatal Case of Toxic Epidermal Necrolysis Caused by Cefozopran and Associated with Psoriasis.
- Sawada Y1, Kabashima-Kubo R, Hino R, Nakamura M.
- Acta dermato-venereologica.Acta Derm Venereol.2014 May 6;94(3):341-342. doi: 10.2340/00015555-1704.
- Abstract is missing (Short).
- PMID 24048229
- Infective endocarditis caused by Listeria monocytogenes forming a pseudotumor.
- Uehara Yonekawa A1, Iwasaka S, Nakamura H, Fukata M, Kadowaki M, Uchida Y, Odashiro K, Shimoda S, Shimono N, Akashi K.
- Internal medicine (Tokyo, Japan).Intern Med.2014;53(9):1029-32. Epub 2014 May 1.
- A 73-year-old woman with breast cancer and metastasis under chemotherapy suffered from fever, pleural effusion and pericardial effusion. Despite the administration of treatment with cefozopran and prednisolone, the patient's fever relapsed. An electrocardiogram identified a new complete atrioventric
- PMID 24785898
- Effect of meropenem with or without immunoglobulin as second-line therapy for pediatric febrile neutropenia.
- Kobayashi R1, Suzuki D, Sano H, Kishimoto K, Yasuda K, Kobayashi K.
- Pediatrics international : official journal of the Japan Pediatric Society.Pediatr Int.2013 Dec 24. doi: 10.1111/ped.12279. [Epub ahead of print]
- BACKGROUND: Meropenem (MEPM) is widely used for treatment of febrile neutropenia. There have been many reports on MEPM for pediatric febrile neutropenia showing success rates of approximately 50-75%. Although i.v. immunoglobulin (IVIG) is widely used for treatment of infection with antibiotics, ther
- PMID 24373032
Japanese Journal
- 市中病院における緑膿菌の抗菌薬感受性検査の推移(2008–2010年):カルバペネム系抗菌薬に対する耐性率の低減に注目して
- 藏前 仁,犬飼 ともみ,奥川 勝 [他],夏目 美恵子,佐藤 浩二,杉浦 充,伊藤 誠,中村 不二雄
- 日本環境感染学会誌 27(3), 220-225, 2012
- 愛知県西三河地区の市中病院で2008年から2010年までの3年間に分離同定され,抗菌薬感受性検査を実施した緑膿菌1343株を対象に,抗菌薬感受性結果の推移を分析した.その結果,カルバペネム系抗菌薬に対する耐性率はIPM/CSで6.4% vs 3.3% (2008年対2010年のデータを対比,以下同様),MEPMで2.7% vs 1.4%と低下傾向を示した.同時にCPFXの耐性率も13.4% v …
- NAID 130002129042
- Rupture of Renal Mycotic Aneurysm that Developed during the Treatment of Streptococcal Infective Endocarditis and Vertebral Osteomyelitis
- Uno Kenji,Kasahara Kei,Komatsu Yuko,Konishi Mitsuru,Yoshihmoto Eiichiro,Maeda Koichi,Mikasa Keiichi
- Internal Medicine 51(10), 1255-1258, 2012
- … A 50-year-old woman received two weeks of cefozopran and two weeks of imipenem for streptococcal endocarditis and vertebral osteomyelitis. …
- NAID 130002062443
- 中西 啓,水田 邦博,大和谷 崇 [他],橋本 泰幸,浜田 登,峯田 周幸
- 耳鼻咽喉科臨床 104(7), 491-498, 2011-07-01
- … Malignant external otitis was diagnosed, and the patient was treated with cefozopran. …
- NAID 10029062733
Related Links
- Cefozopran [CZOP]. セフォゾプラン, セフェム系. 1. 商品名. 先発品. ファーストシン静 注用0.5g/ファーストシン静注用1g/ファーストシン静注用1gバッグS/ファースト シン静注用1gバッグG 【武田薬品工業】. 2. 日本における発売年. 1995(平成7)年. 3. 特長 ...
- Cefozopran. From Wikipedia, the free encyclopedia. Jump to: navigation, search. Cefozopran. Systematic (IUPAC) name ... Cefozopran (INN) is a fourth- generation cephalosporin. v · t · e · Antibacterials: cell envelope antibiotics (J01C- J01D) ...
Related Pictures
★リンクテーブル★
[★]
- 英
- cefozopran CZOP
- 化
- 塩酸セフォゾプラン cefozopran hydrochloride
- 商
- ファーストシン
- 関
- 抗菌薬
[★]
- 関
- cefozopran